Latest Capital Allocation News

Page 3 of 104
TransDigm finished fiscal 2026 with strong sales and adjusted earnings growth, then set a double-digit revenue target for the year ahead. But higher interest costs pushed fourth-quarter GAAP net income lower and debt continued to rise.
Victor Sage
Victor Sage
10 Nov 2026
HyTerra will abandon its 16.03% earn-in interest in Nebraska, crystallising an expected A$7.5 million non-cash impairment while avoiding US$17.33 million in remaining funding commitments. The company is redirecting technical work and capital towards its wholly owned Kansas Rift Play, with drilling deferred until target-ranking work is complete.
Maxwell Dee
Maxwell Dee
10 Nov 2026
Constellation Energy delivered a sharp rise in third-quarter earnings and raised its full-year outlook, backed by stronger market conditions and the contribution from Calpine. The company also lined up new nuclear investment, customer contracts and a potential US$5 billion government-backed financing facility.
Maxwell Dee
Maxwell Dee
9 Nov 2026
Ferguson has raised its 2026 sales and adjusted margin guidance after a strong third quarter, with acquisitions helping offset soft residential markets. The upgrade comes alongside higher debt, paused buybacks and a 40-basis-point decline in gross margin.
Maxwell Dee
Maxwell Dee
9 Nov 2026
NRG Energy delivered a sharp third-quarter earnings lift while agreeing to sell 4.9 GW of natural-gas generation assets to LS Power for US$4 billion. The proceeds are earmarked for heavier share buybacks, debt reduction and potential growth investment, although the transaction still requires regulatory approval.
Maxwell Dee
Maxwell Dee
9 Nov 2026
Berkshire Hathaway delivered lower third-quarter operating earnings and net profit, but its nine-month operating result improved year on year. The conglomerate also repurchased about US$9.6 billion of stock in the quarter, taking 2026 buybacks to US$14.4 billion.
Claire Turing
Claire Turing
9 Nov 2026
Biotron CEO and executive director Glenn Gilbert has started more than two months ahead of schedule, immediately taking charge of a strategic review centred on SedRx. The review will also test development priorities, capital allocation and partnering options across the company’s drug portfolio.
Ada Torres
Ada Torres
9 Nov 2026
Sarytogan Graphite has launched a non-renounceable entitlement offer targeting up to $3.85 million, but only $1 million is underwritten and the issue depends on a Kazakh regulatory permit. The prospectus also flags going-concern uncertainty, substantial future project funding needs and dilution for shareholders who do not participate.
Maxwell Dee
Maxwell Dee
9 Nov 2026
Litchfield Minerals has made a potential Harts Range partnership the centrepiece of its 2027 strategy, with BHP expected to take the project to its investment committee later this month. The explorer is also trimming holding costs, separating non-core assets and seeking a second drill-ready copper or gold project.
Maxwell Dee
Maxwell Dee
9 Nov 2026
PSEG has lifted its five-year regulated investment plan to US$22.5 billion to US$25.5 billion while maintaining its 2026 operating earnings guidance. The utility also outlined nuclear growth options and an indicative dividend increase, though several projects remain subject to regulatory approval.
Maxwell Dee
Maxwell Dee
7 Nov 2026
Third Age Health will acquire 75% of New Zealand asbestos specialist Consultex Group for $3.75 million, adding a new Testing, Inspection & Compliance vertical. The deal will be funded through existing cash and bank debt, with settlement expected by 30 November 2026.
Victor Sage
Victor Sage
6 Nov 2026
Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
Victor Sage
6 Nov 2026

Browse the archive

Full archive